Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Coppo

Showing results (151-160 of 199) with videos related to

Pageof 20
Sort By:
European Journal of Internal Medicine|June 27, 2021
Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMANihal Martis, Matthieu Jamme, Corinne Bagnis-Isnard, et al.
Blood Advances|August 28, 2025
Optimizing ADAMTS13 prophylaxis to reduce relapse and organ failure in congenital thrombotic thrombocytopenic purpuraBérangère S Joly, Adrien Joseph, Raïda Bouzid, et al.
Journal of Thrombosis and Haemostasis : JTH|June 18, 2025
2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpuraX Long Zheng, Zainab Al-Housni, Spero R Cataland, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 27, 2019
Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkersFleuria Meibody, Matthieu Jamme, Vassilis Tsatsaris, et al.
Research and Practice in Thrombosis and Haemostasis|January 19, 2026
Health-related quality of life and mental health in autoimmune thrombotic thrombocytopenic purpura patients in the caplacizumab eraJulia Weisinger, Christina Tites, Laurent Gilardin, et al.
Blood|April 25, 2012
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Ian J Mackie, et al.
Blood|February 5, 2021
N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTPBogac Ercig, Nuno A G Graça, Kadri Kangro, et al.
Haematologica|July 29, 2017
The ADAMTS13<sup>1239-1253</sup> peptide is a dominant HLA-DR1-restricted CD4<sup>+</sup> T-cell epitopeLaurent Gilardin, Sandrine Delignat, Ivan Peyron, et al.
Journal of Thrombosis and Haemostasis : JTH|October 22, 2023
Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpuraLaure De Waele, Kazuya Sakai, Ilaria Mancini, et al.
Transplantation|February 5, 2015
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TCFlore Sicre de Fontbrune, Claire Galambrun, Anne Sirvent, et al.
Pageof 20

Showing results (151-160 of 199) with videos related to

Sort By:
Pageof 20
European Journal of Internal Medicine|June 27, 2021
Systemic autoimmune disorders associated with thrombotic microangiopathy: A cross-sectional analysis from the French National TMA registry: Systemic autoimmune disease-associated TMANihal Martis, Matthieu Jamme, Corinne Bagnis-Isnard, et al.
Blood Advances|August 28, 2025
Optimizing ADAMTS13 prophylaxis to reduce relapse and organ failure in congenital thrombotic thrombocytopenic purpuraBérangère S Joly, Adrien Joseph, Raïda Bouzid, et al.
Journal of Thrombosis and Haemostasis : JTH|June 18, 2025
2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpuraX Long Zheng, Zainab Al-Housni, Spero R Cataland, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 27, 2019
Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkersFleuria Meibody, Matthieu Jamme, Vassilis Tsatsaris, et al.
Research and Practice in Thrombosis and Haemostasis|January 19, 2026
Health-related quality of life and mental health in autoimmune thrombotic thrombocytopenic purpura patients in the caplacizumab eraJulia Weisinger, Christina Tites, Laurent Gilardin, et al.
Blood|April 25, 2012
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpuraLuca A Lotta, Haifeng M Wu, Ian J Mackie, et al.
Blood|February 5, 2021
N-glycan-mediated shielding of ADAMTS13 prevents binding of pathogenic autoantibodies in immune-mediated TTPBogac Ercig, Nuno A G Graça, Kadri Kangro, et al.
Haematologica|July 29, 2017
The ADAMTS13<sup>1239-1253</sup> peptide is a dominant HLA-DR1-restricted CD4<sup>+</sup> T-cell epitopeLaurent Gilardin, Sandrine Delignat, Ivan Peyron, et al.
Journal of Thrombosis and Haemostasis : JTH|October 22, 2023
Open ADAMTS-13 conformation index predicts earlier relapse in immune-mediated thrombotic thrombocytopenic purpuraLaure De Waele, Kazuya Sakai, Ilaria Mancini, et al.
Transplantation|February 5, 2015
Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TCFlore Sicre de Fontbrune, Claire Galambrun, Anne Sirvent, et al.
Pageof 20